Production (Stage)
Xeris Biopharma Holdings, Inc.
XERS
$4.83
-$0.05-1.03%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 29.88% | 23.89% | 22.72% | 35.31% | 41.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.88% | 23.89% | 22.72% | 35.31% | 41.18% |
| Cost of Revenue | 35.13% | 28.58% | 27.62% | 20.91% | 35.13% |
| Gross Profit | 28.79% | 22.89% | 21.66% | 38.52% | 42.50% |
| SG&A Expenses | 8.05% | 7.73% | 13.80% | 10.55% | 12.63% |
| Depreciation & Amortization | -0.01% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.45% | 10.91% | 15.96% | 11.65% | 16.29% |
| Operating Income | 63.56% | 37.41% | 5.61% | 39.75% | 30.43% |
| Income Before Tax | 27.08% | 10.08% | -3.91% | 18.83% | 17.07% |
| Income Tax Expenses | -173.35% | -81.59% | -85.34% | 135.65% | 7.28% |
| Earnings from Continuing Operations | 30.01% | 11.92% | -2.13% | 16.62% | 17.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.01% | 11.92% | -2.13% | 16.62% | 17.20% |
| EBIT | 63.56% | 37.41% | 5.61% | 39.75% | 30.43% |
| EBITDA | 86.74% | 51.15% | 6.87% | 49.39% | 37.59% |
| EPS Basic | 35.13% | 16.87% | 2.64% | 19.41% | 18.68% |
| Normalized Basic EPS | 41.14% | 24.36% | 0.17% | 24.82% | 15.91% |
| EPS Diluted | 35.13% | 16.87% | 2.64% | 19.41% | 18.68% |
| Normalized Diluted EPS | 41.14% | 24.36% | 0.17% | 24.82% | 15.91% |
| Average Basic Shares Outstanding | 8.09% | 6.59% | 5.00% | 3.41% | 1.73% |
| Average Diluted Shares Outstanding | 8.09% | 6.59% | 5.00% | 3.41% | 1.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |